LUT014Recent news mentioning LUT0142026-09-16 — Lutris Pharma to Present Updated Data from Its Phase 2 Trial of LUT014 Gel for the Treatment of Patients With EGFRI-Induced Acneiform Rash at the EADV CongressAppears alongsideEADVBrowse the full archive →